OBJECTIVES: Among mental disorders, schizophrenia (SCZ) is the most disabling disease. The genetic polymorphisms of CYP2E1 gene are reported to be related to the development of several mental diseases. The purpose of this present study was to examine the association between the CYP2E1 (rs2070673) gene polymorphisms and schizophrenia in the Bangladeshi population. METHODS: Genotyping of this gene was done by extracting DNA from 101 Schizophrenic patients and 101 healthy volunteers, after than polymerase chain reaction (PCR) was carried out for amplification of extracted DNA. After amplification, the respective DNA fragments were digested by restriction enzyme BspMI and finally expected DNA fragments were observed by agarose gel electrophoresis technique. RESULTS: We found that patients carrying AT genotype had shown a significantly higher risk (p< 0.05) for the development of schizophrenia in compared to patients carrying TT genotype. Whereas patients carrying AA genotype revealed a higher risk for the development of schizophrenia in compared to patients carrying TT genotype and this result was found statistically significant (p< 0.05). For combined model i.e. patients carrying AT+AA genotype had shown a similar scenario of higher risk for the development of schizophrenia in compared to patients carrying TT genotype (p< 0.05). CONCLUSIONS: So, in the context of Bangladeshi Schizophrenia patients, our result indicates that allele rs2070673 (CYP2E1*7) is associated with the higher risk of schizophrenia. As we have identified the genetic basis of the Bangladeshi schizophrenia patients, we hope it will be helpful for the treatment selection of schizophrenia patients.
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IS THE RISK OF DEVELOPING DEPRESSIVE DISORDER FOLLOWING OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS DIFFERENT?
Hsieh C 1 , Wei Y 2 , Lin W 2 1 Oriental Institute of Technology, New Taipei City, Taiwan, 2 Chang Jung Christian University, Tainan, Taiwan OBJECTIVES: Rheumatoid arthritis (RA) and Osteoarthritis (OA) are the most common chronic disability diseases. The course of these two diseases is long. Many studies showed that the risk of the depressive disorder in patients with OA or RA were higher than general population. However, few study examine the difference of depression risk between patients with OA and RA in Taiwan. This study aim at comparing the risk of depression onset between RA and OA patients. METHODS: This is a nationwide retrospective cohort study using data (1997 to 2013) from a 100 million of randomly sampled NHI beneficiaries' enrollment. Newly diagnosed RA patients were identified by ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification), and OA patients were selected with propensity score matching. All the matched cohort participants were followed up to December 31, 2013 or the date of their death to check the occurrence of their first onset of depression, and those without onset of depression were censored on. The Cox proportional-hazard regression was used to estimate the risk of depression onset. RESULTS: We identified a total of 796 subjects with a newly diagnosed RA and a total of 98,422 subjects with OA from January 1, 1997 to December 31, 2013.Using the propensity score matching, we selected 775 RA cases and 2,325 OA cases. The onset of depressive disorder in the RA cohort (30.71 months) is earlier than in the OA cohort (38.16 months). The RA cohort have the higher risk of depression onset and the hazard ratio (HR) was 2.19-fold in the RA cohort than in the OA cohort (95% confidence interval = 1.47-3.27). CONCLUSIONS: Patients with RA have a significantly higher risk of depression than the OA patients. Therefore, the assessment of the mental health status for RA patients should be taken into consideration for appropriate care. OBJECTIVES: At present, schizophrenia guidelines recommend waiting for 8 weeks before considering a patient as non-responder. This study aims to assess whether the early response (week 3 and 4) can predict the outcome at 8th week of treatment using risperidone among first episode schizophrenia (FES). METHODS: A prospective observational study was conducted in 48 adult FES patients with three points follow up (week 3,4 and 8). Patients with any other psychiatric co-morbidities and/ or taking any other antipsychotics were excluded from the study. A reduction of 25% in PANNS score from the base line at week 3 and 30% at week 4 were considered as early response. A reduction of 50% at week 8 was considered as responders. Receiver Operating Characteristics (ROC) curves were implemented to detect the optimal threshold of early response (AUC> 80%) at 3rd and 4th week. To identify the variables that are predictive of treatment responses at Week 8, binary logistic regression was performed. RESULTS: The mean total PANSS baseline score of the study population was 108.98 (95% C.I:102.85-115.10). Week 3 response can be taken for the prediction of 8th week response (AUC= 85.4, P< 0.001, specificity= 89%, sensitivity= 70%, Positive Predictive Value (PPV)= 68%, Negative Predictive Value (NPV)= 98% and Optimum Early Response (OER) was < 24.5% reduction in PANSS score). However more accurate prediction can be possible with week 4 response (AUC = 88.7%, P< 0.001, specificity= 94%, sensitivity= 73.3%, PPV= 98%, NPV= 96% and OER was < 28% reduction. 31 patients (65%) achieved more than 50% reduction (responders) in PANSS score by week 8. Independent predictors for good treatment responses at Week 8 were female gender (P= 0.048), a higher educational level(P= 0.036) and non-smoking(P= 0.004). CONCLUSIONS: Our study suggests that patients with early response at week 3 are likely to achieve positive response after 8 weeks. This may help in appropriate clinical decision making for early non-responders with treatment modifications.
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PMH7 FINDING EARLY IMPROVEMENT THRESHOLD TO PREDICT RESPONSE AFTER 8 WEEKS OF TREATMENT USING OLANZAPINE IN FIRST-EPISODE SCHIZOPHRENIA
Subeesh V 1 , Singh H 2 , Maheswari E 3 , Saraswathy GR 4 , Minnikanti SS 5 1 M S Ramaiah University of Applied Sciences, Bangalore, India, 2 Ramaiah Medical College, Bengalore, India, 3 M.S. Ramaiah University of Applied Sciences, Bangalore, India, 4 Faculty of Pharmacy, Ramaiah University of Applied Sciences, Bangalore, India, 5 M S Ramaiah University of Applied Sciences, Bengalore, India OBJECTIVES: Presently, schizophrenia guidelines recommend waiting for 8 weeks before considering a patient as non-responder. This study aims to assess whether the early response (week 2,3 and 4) can predict the outcome at 8th week for the treatment of first episode schizophrenia (FES) using olanzapine. METHODS: A prospective observational study was conducted in 36 adult FES patients with four points follow up (week 2,3,4 and 8). Patients with any other psychiatric co-morbidities and/or taking any antipsychotics were excluded from the study. A reduction of 25% in PANNS score from the base line at week 3 and 30% at week 4 were considered as early response. A reduction of 50% at week 8 was considered as responders. Receiver Operating Characteristics (ROC) curves were implemented to detect the optimal threshold of early response (AUC> 80%) at 2nd, 3rd and 4th weeks. To identify the variables that are predictive of treatment responses at Week 8, binary logistic regression was performed. RESULTS: The mean total PANSS baseline score of the study population was 106.66 (95% C.I, 100.4-112.9). Week 2 (AUC= 50.5, P= 0.964) and week 3 (AUC= 64.9, P= 0.136) responses failed to predict the 8th week response. Week 4 response (AUC = 92%, P< 0.001) can be taken for the prediction of 8th week response (specificity= 72%, sensitivity= 100%, Positive Predictive Value= 61.1%, Negative Predictive Value= 100% and OER was < 29.4% reduction). 25 patients (69%) achieved more than 50% reduction (responders) in PANSS score after 8 weeks of treatment. Independent predictors for good treatment responses at Week 8 were female gender (P= 0.032), a higher educational level(P= 0.021) and non-smoking(P= 0.014) and non-alcoholics (P= 0.048). CONCLUSIONS: Our study suggests that patients with early response at week 4 are likely to achieve positive response after 8 weeks. This may help in appropriate clinical decision making for early non-responders.
PMH8 THE RISK OF DEMENTIA AND THE ANTICHOLINERGIC MEDICATION USE AMONG PATIENTS WITH PARKINSON'S DISEASE: RESULTS FROM NATIONAL HEALTH INSURANCE RESEARCH DATABASE IN TAIWAN
Wu C 1 , Sheu J 2 , Tsai M 3 1 Taipei Medical University, Taipei, Taiwan, 2 Taipei Medical University Hospital, Taipei, Taiwan, 3 Abbvie Biopharmaceuticals GmbH Taiwan Branch, Taipei, Taiwan OBJECTIVES: Recent studies raised concerns about the potential link between anticholinergic medication use and an increased risk of cognitive impairment. However, whether taking anticholinergic medications was associated with a longterm and irreversible cognitive impairment such as dementia remains unknown. The purpose of this study was to evaluate the association between anticholinergic medication use and the risk of dementia among patients with Parkinson's disease. METHODS: We conducted a retrospective cohort study with a new anticholinergic drug user design using an 11-years (2001-2011) National Health Insurance Research Database (NHIRD) in Taiwan. Patients were included if they were diagnosed
